Re Contract

1 Apr 2005 06:00

PRESS RELEASE PROTEOSHOP COLLABORATION WITH REGEN THERAPEUTICS Proteome Sciences plc ('Proteome Sciences') is pleased to announce a ProteoSHOPcollaboration funded by ReGen Therapeutics plc ('ReGen') for thecharacterization of Colostrinin, a proline-rich polypeptide complex derivedfrom bovine colostrum, which ReGen are developing as a human and veterinarynutraceutical. ReGen also believes that the peptides within Colostrinin, orsmall molecular weight compounds based on them, may have potential aspharmaceutical agents for the treatment of Alzheimer's and otherneurodegenerative diseases.Proteome Sciences will apply its ProteoSHOP proteomic technologies to thebiochemical characterization and activity profiling of Colostrinin. Thisfollows an earlier proteomic study for ReGen undertaken by Proteome Sciences tocompare the expression of proteins from neuronal cells before and aftertreatment with Colostrinin.Financial details of the collaboration were not disclosed.Commenting on the announcement, Christopher Pearce, Chief Executive of ProteomeSciences said:'We are delighted to be collaborating further with ReGen and helping themidentify the bioactive components of Colostrinin. By combining our ProteoSHOPtoolkit with the expertise we have already developed in Alzheimer's and otherneurodegenerative diseases, Proteome Sciences is uniquely positioned toundertake this project'.For further information please contact:Proteome Sciences plcwww.proteomics.comChristopher Pearce, Chief Executive Tel: +44 (0)1932 865065 Email: christopher.pearce@proteomics.comPublic Relations for Proteome SciencesIKON AssociatesAdrian Shaw Tel: +44 (0)1483 535102 Mobile: +44 (0)797 9900733 Email: adrian@ikonassociates.com Notes to Editors:Proteome Sciences plc applies high sensitivity proteomics to identify andcharacterise differential protein expression in diseases for diagnostic,prognostic and therapeutic applications. It has to date developed sensitiveblood assays for stroke, vCJD, BSE, solid organ transplant rejection andAlzheimer's disease. The main focus of its research currently addressesneurological, neurodegenerative, diabetes/obesity, oncology and cardiovascularconditions.In addition to its own proprietary biomarkers, Proteome Sciences has developedProteoSHOP (Proteome Sciences High Output Proteomics), a toolbox that offershigh sensitivity and high throughput gel and gel-free proprietary technologiesfor the identification of potential biomarkers and drug targets. Theseinclude specialisation in membrane proteins and protein phosphorylation. The Company has also developed a range of specialist reagents to improve theperformance and quantitation of protein separation and characterisation withmass spectrometry, bioinformatics, statistics and pattern recognition. Theseinclude Sensitizer, PST, qPST and TMT.The process of commercialisation is being actively pursued across the portfolioof the Company's programmes and technologies and to date licensing deals havebeen signed for the commercialisation of tests for Stroke and TSEs.Proteome Sciences is headquartered in Cobham, Surrey in the UK and haslaboratories at Kings College Hospital, London and in Frankfurt. It employs 40full time scientists in addition to its corporate and business developmentstaff. The Company is listed on the Alternative Investment Market. ENDS ENDPROTEOME SCIENCES PLC